Drugs News and Research

RSS

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

SRI International awarded NIDA contract to study new treatment therapies for substance abuse

SRI International has been awarded a five-year contract valued up to $9.75 million from the National Institute on Drug Abuse to conduct preclinical safety studies of potential new medications to treat substance abuse. SRI researchers will study potential drug-drug interactions between new treatment therapies and common drugs of abuse to assess potential adverse reactions.

6 Nov 2013

Johnson & Johnson to pay $2.2 billion fine to resolve drug marketing case

The government alleged that the drug company and its subsidiaries promoted psychiatric medications for uses that had not been approved by the Food and Drug Administration.

6 Nov 2013

Scientists investigate combined action of two different compounds against CML

Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek's group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang Jahnke and colleagues from Novartis, has investigated the combined action of two different compounds against this form of leukemia.

6 Nov 2013

Researchers on the way to find cure against African sleeping sickness

Researchers at Umeå University have identified drugs targeting infections of the parasite Trypanosoma brucei and are thereby well on the way to find a cure against African sleeping sickness. This is the kernel of a thesis, which will be publicly defended on 8 November 2013.

6 Nov 2013

SCOTUS won't hear appeal seeking to reinstate Okla. abortion law

The U.S. Supreme Court is refusing to hear an appeal seeking to reinstate an Oklahoma law that would effectively ban abortion-inducing drugs. In Texas, opponents of an abortion law are appealing to the Supreme Court to reinstate their injunction against the law that requires those performing the procedure have admitting privileges at nearby hospitals.

6 Nov 2013

Research: Chronic stress changes gene activity in immune cells before reaching bloodstream

New research shows that chronic stress changes gene activity in immune cells before they reach the bloodstream. With these changes, the cells are primed to fight an infection or trauma that doesn't actually exist, leading to an overabundance of the inflammation that is linked to many health problems.

6 Nov 2013

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

Researchers have linked a species of intestinal bacteria known as Prevotella copri to the onset of rheumatoid arthritis, the first demonstration in humans that the chronic inflammatory joint disease may be mediated in part by specific intestinal bacteria.

6 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Ventana partners with Incyte to develop companion diagnostic tests for oncology drug programs

Ventana Medical Systems, Inc., a member of the Roche Group, today announced that it has entered into an agreement with Incyte Corporation to collaborate on the development of companion diagnostic tests for Incyte's oncology drug programs, beginning with the Incyte IDO1 inhibitor program.

5 Nov 2013

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

5 Nov 2013

First Edition: November 5, 2013

Today's headlines include continuing coverage of the implementation issues that are plaguing the health law, as well as President Barack Obama's pledge to campaign for the overhaul's success.

5 Nov 2013

NTU establishes new $60 million research institute in Nanomedicine

Nanyang Technological University is giving the development of nanotechnology a big boost, by establishing a new $60 million research institute in Nanomedicine, which focuses on the medical application of nanotechnology. An emerging field in drugs, nanomedicine are made up of tiny nano-sized particles thousands of times smaller than a grain of sand.

5 Nov 2013

Gene mutated in rare hereditary disorder also prevents mTORC1 pathway activation

Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dub- cancer syndrome also prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway.

5 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

On behalf of the U.S. Food and Drug Administration, the U.S. Department of Justice today announced a guilty plea agreement with Janssen Pharmaceuticals, Inc., of Titusville, N.J., and a $400 million criminal fine for introducing a misbranded drug, Risperdal (risperidone), into interstate commerce.

5 Nov 2013

Researchers identify factor that promotes metastasis of colon tumors

Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified a factor that promotes metastasis of colon tumors - and presents a possible target for therapy.

5 Nov 2013

Officials give drug companies the OK to help patients with costly drug co-pays in insurance exchanges

Federal officials last week OK'd allowing pharmaceutical companies to help cover patient out-of-pocket costs for costly drugs in the health law's insurance exchanges, a closely watched move by drug companies and patient advocates.

5 Nov 2013

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announced today top-line results from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.

5 Nov 2013

Blood pressure tailored treatment reduces individual's risk of heart disease and strokes

A new way of using blood pressure-lowering medications could prevent more than a fourth of heart attacks and strokes - up to 180,000 a year - while using less medication overall, according to new research from the University of Michigan Health System and the VA Ann Arbor Healthcare System.

4 Nov 2013

Drugs News and Research

New treatment option for patients with most difficult-to-treat forms of hepatitis C

SRI International awarded NIDA contract to study new treatment therapies for substance abuse

Johnson & Johnson to pay $2.2 billion fine to resolve drug marketing case

Scientists investigate combined action of two different compounds against CML

Researchers on the way to find cure against African sleeping sickness

SCOTUS won't hear appeal seeking to reinstate Okla. abortion law

Research: Chronic stress changes gene activity in immune cells before reaching bloodstream

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Ventana partners with Incyte to develop companion diagnostic tests for oncology drug programs

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

First Edition: November 5, 2013

NTU establishes new $60 million research institute in Nanomedicine

Gene mutated in rare hereditary disorder also prevents mTORC1 pathway activation

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

Researchers identify factor that promotes metastasis of colon tumors

Officials give drug companies the OK to help patients with costly drug co-pays in insurance exchanges

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Blood pressure tailored treatment reduces individual's risk of heart disease and strokes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News